Share Price and Basic Stock Data
Last Updated: September 15, 2025, 8:42 pm
PEG Ratio | 0.00 |
---|
Quick Insight
JHS Svendgaard Laboratories Ltd, a player in the personal care industry, currently trades at ₹11.4 with a MarketCap of ₹97.1 Cr. The company's financial metrics reveal a mixed picture – with a P/E ratio unavailable, ROE stands at 10.8%, ROCE at 5.19%, and OPM at 7.08%. Notably, the company has a negative Net Profit of -₹20 Cr, with Promoters holding 34.56%, FIIs at 1.59%, and Public at 63.86%. JHS Svendgaard's Reserves amount to ₹87 Cr, Borrowings at ₹6 Cr, and a CCC of 63 days. The P/BV ratio stands at 0.75x, while the ICR is at 7.34x.
Strengths of JHS Svendgaard include a relatively healthy ROE and a comfortable Interest Coverage Ratio. However, the company faces significant risks due to its negative Net Profit, low ROCE, and high reliance on short-term borrowings. Looking ahead, improving operational efficiency, enhancing profitability through cost optimization, and exploring new product lines could bolster the company's prospects. On the flip side, failure to address its financial weaknesses and adapt to evolving industry trends could further challenge its sustainability in the competitive personal care sector. In a sector where profitability and innovation are key drivers, investors should closely monitor JHS Svendgaard's ability to turnaround its financial performance to ensure sustainable long-term growth.
Competitors of JHS Svendgaard Laboratories Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Honasa Consumer Ltd | 9,741 Cr. | 300 | 494/190 | 137 | 36.9 | 0.00 % | 7.50 % | 5.93 % | 10.0 |
Ambica Agarbathies Aroma & Industries Ltd | 45.0 Cr. | 26.4 | 37.0/24.0 | 88.3 | 63.6 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
Ador Multi Products Ltd | 93.1 Cr. | 97.4 | 119/23.4 | 19.4 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
Kaya Ltd | 531 Cr. | 406 | 510/204 | 106 | 0.00 % | 2.50 % | % | 10.0 | |
Jyothy Labs Ltd | 11,942 Cr. | 325 | 573/268 | 32.6 | 55.8 | 1.08 % | 24.6 % | 19.0 % | 1.00 |
Industry Average | 82,331.92 Cr | 2,090.51 | 62.25 | 107.49 | 0.76% | 29.21% | 23.94% | 4.94 |
Quarterly Result
Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 21.31 | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 |
Expenses | 22.77 | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 |
Operating Profit | -1.46 | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 |
OPM % | -6.85% | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% |
Other Income | 1.48 | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 |
Interest | 0.68 | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 |
Depreciation | 1.70 | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 |
Profit before tax | -2.36 | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 |
Tax % | 75.85% | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% |
Net Profit | -4.16 | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 |
EPS in Rs | -0.59 | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 |
Last Updated: August 20, 2025, 8:40 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.17 Cr. (Mar 2025) to 23.45 Cr., marking a decrease of 1.72 Cr..
- For Expenses, as of Jun 2025, the value is 21.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 30.55 Cr. (Mar 2025) to 21.79 Cr., marking a decrease of 8.76 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.66 Cr.. The value appears strong and on an upward trend. It has increased from -5.38 Cr. (Mar 2025) to 1.66 Cr., marking an increase of 7.04 Cr..
- For OPM %, as of Jun 2025, the value is 7.08%. The value appears strong and on an upward trend. It has increased from -21.37% (Mar 2025) to 7.08%, marking an increase of 28.45%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.44 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 2.44 Cr..
- For Interest, as of Jun 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.21 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 1.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.02 Cr. (Mar 2025) to 1.88 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.62 Cr.. The value appears strong and on an upward trend. It has increased from -9.05 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 9.67 Cr..
- For Tax %, as of Jun 2025, the value is -69.35%. The value appears to be improving (decreasing) as expected. It has decreased from -23.09% (Mar 2025) to -69.35%, marking a decrease of 46.26%.
- For Net Profit, as of Jun 2025, the value is 1.06 Cr.. The value appears strong and on an upward trend. It has increased from -6.96 Cr. (Mar 2025) to 1.06 Cr., marking an increase of 8.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.81 (Mar 2025) to 0.12, marking an increase of 0.93.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: September 15, 2025, 4:51 am
Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 35 | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 91 |
Expenses | 39 | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 95 |
Operating Profit | -4 | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | -4 |
OPM % | -11% | -7% | 7% | 11% | 10% | 0% | 1% | 2% | -1% | -11% | -1% | -4% | -5% |
Other Income | -3 | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 1 |
Interest | 14 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
Depreciation | 15 | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 |
Profit before tax | -35 | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -12 |
Tax % | -18% | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4,000% | -24% | 18% | 58% | |
Net Profit | -29 | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -18 |
EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -2.11 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 24.14% | 0.00% | 200.00% | 18.18% | -107.69% | -150.00% | 120.00% | -500.00% | -350.00% | 77.78% | -400.00% |
Change in YoY Net Profit Growth (%) | 0.00% | -24.14% | 200.00% | -181.82% | -125.87% | -42.31% | 270.00% | -620.00% | 150.00% | 427.78% | -477.78% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | -8% |
3 Years: | 2% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | -2% |
5 Years: | % |
3 Years: | % |
TTM: | -624% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | -9% |
3 Years: | -23% |
1 Year: | -61% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 0% |
3 Years: | 0% |
Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: September 10, 2025, 1:54 pm
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 24 | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 |
Reserves | 38 | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 |
Borrowings | 54 | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 |
Other Liabilities | 74 | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 |
Total Liabilities | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 |
Fixed Assets | 121 | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 |
CWIP | 0 | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 |
Investments | 0 | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 |
Other Assets | 70 | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 |
Total Assets | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 78.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 8.00 Cr..
- For Reserves, as of Mar 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Mar 2024) to 87.00 Cr., marking a decrease of 4.00 Cr..
- For Borrowings, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 204.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 90.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 8.00 Cr..
- For Total Assets, as of Mar 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..
Notably, the Reserves (87.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -58.00 | -23.00 | 4.00 | 10.00 | 12.00 | -7.00 | -7.00 | -5.00 | -7.00 | -12.00 | -6.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | -0.52 | -2.34 | -0.63 | 0.20 | -0.32 |
Diluted EPS (Rs.) | -0.52 | -2.34 | -0.63 | 0.20 | -0.32 |
Cash EPS (Rs.) | 0.29 | -1.43 | 0.42 | 1.33 | 0.64 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 21.67 | 27.78 | 30.05 | 30.74 | 30.31 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 21.67 | 27.78 | 30.05 | 30.74 | 30.31 |
Revenue From Operations / Share (Rs.) | 9.03 | 14.82 | 13.29 | 15.65 | 22.84 |
PBDIT / Share (Rs.) | 0.43 | 0.81 | 1.32 | 1.47 | 2.55 |
PBIT / Share (Rs.) | -0.37 | -0.33 | 0.23 | 0.34 | 1.11 |
PBT / Share (Rs.) | -0.43 | -3.37 | 0.01 | 0.15 | -0.95 |
Net Profit / Share (Rs.) | -0.51 | -2.58 | -0.66 | 0.20 | -0.79 |
NP After MI And SOA / Share (Rs.) | -0.51 | -2.38 | -0.62 | 0.18 | -0.32 |
PBDIT Margin (%) | 4.77 | 5.50 | 9.91 | 9.39 | 11.14 |
PBIT Margin (%) | -4.19 | -2.25 | 1.73 | 2.19 | 4.84 |
PBT Margin (%) | -4.84 | -22.70 | 0.11 | 0.96 | -4.20 |
Net Profit Margin (%) | -5.73 | -17.43 | -4.97 | 1.33 | -3.48 |
NP After MI And SOA Margin (%) | -5.73 | -16.07 | -4.69 | 1.18 | -1.42 |
Return on Networth / Equity (%) | -2.38 | -8.96 | -2.17 | 0.63 | -1.11 |
Return on Capital Employeed (%) | -1.70 | -1.09 | 0.73 | 1.07 | 3.50 |
Return On Assets (%) | -2.05 | -6.54 | -1.82 | 0.52 | -0.82 |
Total Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover Ratio (%) | 0.32 | 0.41 | 0.36 | 0.42 | 0.59 |
Current Ratio (X) | 1.87 | 2.36 | 4.18 | 5.23 | 2.69 |
Quick Ratio (X) | 1.33 | 2.00 | 3.54 | 4.73 | 2.57 |
Inventory Turnover Ratio (X) | 3.11 | 4.36 | 5.16 | 8.94 | 15.68 |
Interest Coverage Ratio (X) | 7.34 | 5.09 | 6.13 | 7.63 | 7.94 |
Interest Coverage Ratio (Post Tax) (X) | -7.82 | 2.78 | -2.08 | 2.08 | 3.96 |
Enterprise Value (Cr.) | 121.69 | 70.51 | 136.74 | 117.07 | 51.74 |
EV / Net Operating Revenue (X) | 1.72 | 0.73 | 1.59 | 1.16 | 0.37 |
EV / EBITDA (X) | 36.03 | 13.31 | 15.99 | 12.37 | 3.34 |
MarketCap / Net Operating Revenue (X) | 1.81 | 1.06 | 1.55 | 1.27 | 0.32 |
Price / BV (X) | 0.75 | 0.59 | 0.71 | 0.68 | 0.25 |
Price / Net Operating Revenue (X) | 1.81 | 1.06 | 1.55 | 1.27 | 0.32 |
EarningsYield | -0.03 | -0.15 | -0.03 | 0.01 | -0.04 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -0.52. This value is below the healthy minimum of 5. It has increased from -2.34 (Mar 23) to -0.52, marking an increase of 1.82.
- For Diluted EPS (Rs.), as of Mar 24, the value is -0.52. This value is below the healthy minimum of 5. It has increased from -2.34 (Mar 23) to -0.52, marking an increase of 1.82.
- For Cash EPS (Rs.), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 3. It has increased from -1.43 (Mar 23) to 0.29, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 21.67. It has decreased from 27.78 (Mar 23) to 21.67, marking a decrease of 6.11.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 21.67. It has decreased from 27.78 (Mar 23) to 21.67, marking a decrease of 6.11.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 9.03. It has decreased from 14.82 (Mar 23) to 9.03, marking a decrease of 5.79.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 0.43. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.43, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 24, the value is -0.37. This value is below the healthy minimum of 0. It has decreased from -0.33 (Mar 23) to -0.37, marking a decrease of 0.04.
- For PBT / Share (Rs.), as of Mar 24, the value is -0.43. This value is below the healthy minimum of 0. It has increased from -3.37 (Mar 23) to -0.43, marking an increase of 2.94.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -0.51. This value is below the healthy minimum of 2. It has increased from -2.58 (Mar 23) to -0.51, marking an increase of 2.07.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -0.51. This value is below the healthy minimum of 2. It has increased from -2.38 (Mar 23) to -0.51, marking an increase of 1.87.
- For PBDIT Margin (%), as of Mar 24, the value is 4.77. This value is below the healthy minimum of 10. It has decreased from 5.50 (Mar 23) to 4.77, marking a decrease of 0.73.
- For PBIT Margin (%), as of Mar 24, the value is -4.19. This value is below the healthy minimum of 10. It has decreased from -2.25 (Mar 23) to -4.19, marking a decrease of 1.94.
- For PBT Margin (%), as of Mar 24, the value is -4.84. This value is below the healthy minimum of 10. It has increased from -22.70 (Mar 23) to -4.84, marking an increase of 17.86.
- For Net Profit Margin (%), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. It has increased from -17.43 (Mar 23) to -5.73, marking an increase of 11.70.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 8. It has increased from -16.07 (Mar 23) to -5.73, marking an increase of 10.34.
- For Return on Networth / Equity (%), as of Mar 24, the value is -2.38. This value is below the healthy minimum of 15. It has increased from -8.96 (Mar 23) to -2.38, marking an increase of 6.58.
- For Return on Capital Employeed (%), as of Mar 24, the value is -1.70. This value is below the healthy minimum of 10. It has decreased from -1.09 (Mar 23) to -1.70, marking a decrease of 0.61.
- For Return On Assets (%), as of Mar 24, the value is -2.05. This value is below the healthy minimum of 5. It has increased from -6.54 (Mar 23) to -2.05, marking an increase of 4.49.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.02. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.02, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.32. It has decreased from 0.41 (Mar 23) to 0.32, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 24, the value is 1.87. This value is within the healthy range. It has decreased from 2.36 (Mar 23) to 1.87, marking a decrease of 0.49.
- For Quick Ratio (X), as of Mar 24, the value is 1.33. This value is within the healthy range. It has decreased from 2.00 (Mar 23) to 1.33, marking a decrease of 0.67.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.11. This value is below the healthy minimum of 4. It has decreased from 4.36 (Mar 23) to 3.11, marking a decrease of 1.25.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 7.34. This value is within the healthy range. It has increased from 5.09 (Mar 23) to 7.34, marking an increase of 2.25.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -7.82. This value is below the healthy minimum of 3. It has decreased from 2.78 (Mar 23) to -7.82, marking a decrease of 10.60.
- For Enterprise Value (Cr.), as of Mar 24, the value is 121.69. It has increased from 70.51 (Mar 23) to 121.69, marking an increase of 51.18.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.72. This value is within the healthy range. It has increased from 0.73 (Mar 23) to 1.72, marking an increase of 0.99.
- For EV / EBITDA (X), as of Mar 24, the value is 36.03. This value exceeds the healthy maximum of 15. It has increased from 13.31 (Mar 23) to 36.03, marking an increase of 22.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.06 (Mar 23) to 1.81, marking an increase of 0.75.
- For Price / BV (X), as of Mar 24, the value is 0.75. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 23) to 0.75, marking an increase of 0.16.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.06 (Mar 23) to 1.81, marking an increase of 0.75.
- For EarningsYield, as of Mar 24, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.15 (Mar 23) to -0.03, marking an increase of 0.12.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -5.73%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.7% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -2.38% (Industry Average ROE: 23.94%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -7.82
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.33
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 62.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -5.73%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | cs@svendgaard.com http://www.svendgaard.com |
Management | |
---|---|
Name | Position Held |
Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
Mr. Nikhil Nanda | Managing Director |
Mr. Vinay Mittal | Non Executive Director |
Mr. Mukul Pathak | Independent Director |
Mr. Kapil Minocha | Independent Director |
Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 15 September 2025) is 26.70 which is 134.21% higher the current market price of 11.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹97.1 Cr. market cap, FY2025-2026 high/low of 32.9/9.90, reserves of ₹87 Cr, and liabilities of 204 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 97.1 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 15 September 2025?
The current stock price of JHS Svendgaard Laboratories Ltd as on 15 September 2025 is 11.4.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is 32.9/9.90.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.2.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.